Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Rubomycin incorporation into multilayer liposomes]

G A Popov, P I Goncharov

    Antibiotiki
    |May 1, 1980
    PubMed
    Summary

    Rubomycin incorporation into phosphatidylcholine liposomes is most efficient in the lipid phase (70%) at a 1:10 rubomycin to lecithin ratio. Optimal liposome formulations retain rubomycin for 7 days with minimal drug loss.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Search for narrow tt resonances in pp collisions at square root of (s)=1.8 TeV.

    Physical review letters·2004
    Same author

    A precision measurement of the mass of the top quark.

    Nature·2004
    Same author

    Search for large extra dimensions in the monojet+E(T) channel with the DØ detector.

    Physical review letters·2003
    Same author

    Search for the production of single sleptons through R-parity violation in pp; collisions at square root (s) =1.8 TeV.

    Physical review letters·2002
    Same author

    Search for R-parity violating supersymmetry in two-muon and four-jet topologies.

    Physical review letters·2002
    Same author

    Search for leptoquark pairs decaying into nunu+jets in pp collisions at square root[s] = 1.8 TeV.

    Physical review letters·2002

    Area of Science:

    • Pharmacology
    • Drug Delivery Systems
    • Lipid Nanoparticles

    Context:

    • Investigating rubomycin (an anthracycline antibiotic) delivery using liposomes.
    • Evaluating the impact of formulation parameters on drug incorporation and stability.
    • Exploring phosphatidylcholine liposomes as a potential drug carrier system.

    Purpose:

    • To quantitatively characterize rubomycin incorporation into sound-treated phosphatidylcholine liposomes.
    • To assess the stability and preservation of rubomycin properties within liposomes during storage.
    • To determine optimal conditions for maximizing rubomycin encapsulation efficiency.

    Summary:

    • Rubomycin incorporation into the lipid phase of phosphatidylcholine liposomes was significantly more efficient (70%) than into the aqueous phase (≤5%).
    • Maximum incorporation occurred at a rubomycin to phosphatidylcholine molecular ratio of approximately 1:10.
    • Increased cholesterol content and extended sonication time reduced rubomycin incorporation into multilayer liposomes.
    • Optimal liposome formulations exhibited minimal rubomycin loss (5-10%) after 7 days of storage.

    Impact:

    • Provides crucial data for optimizing liposomal rubomycin formulations for enhanced therapeutic efficacy.
    • Highlights the importance of lipid phase incorporation for efficient drug loading.
    • Establishes guidelines for formulation development to ensure drug stability and minimize degradation.
    • Contributes to the advancement of nanoparticle-based drug delivery systems for cancer chemotherapy.

    Related Experiment Videos